Literature DB >> 10673478

The pharmacological properties of tiotropium.

P J Barnes1.   

Abstract

Tiotropium is a long-acting anticholinergic drug. Studies with cloned human muscarinic receptors show that tiotropium binds equally well to M(1), M(2), and M(3) receptors. However, it dissociates very slowly from M(1) and M(3) receptors compared with ipratropium, and more rapidly from M(2) receptors. Binding studies with [(3)H]tiotropium in human lung show that it is approximately 10-fold more potent than ipratropium. In vitro, tiotropium has a potent inhibitory effect against cholinergic nerve-induced contraction of airways. It dissociates extremely slowly, compared with the dissociation of atropine and ipratropium. Clinical studies with single doses of inhaled tiotropium confirm that it is a potent and long-lasting bronchodilator. Furthermore, it protects against cholinergic bronchoconstriction for > 24 h. Pharmacokinetic studies show that little of the inhaled drug is absorbed, thus predicting a high margin of safety.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10673478     DOI: 10.1378/chest.117.2_suppl.63s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  45 in total

1.  Tiotropium bromide step-up therapy for adults with uncontrolled asthma.

Authors:  Stephen P Peters; Susan J Kunselman; Nikolina Icitovic; Wendy C Moore; Rodolfo Pascual; Bill T Ameredes; Homer A Boushey; William J Calhoun; Mario Castro; Reuben M Cherniack; Timothy Craig; Loren Denlinger; Linda L Engle; Emily A DiMango; John V Fahy; Elliot Israel; Nizar Jarjour; Shamsah D Kazani; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira Lugogo; Richard J Martin; Deborah A Meyers; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stanley J Szefler; Stephen I Wasserman; Michael J Walter; Michael E Wechsler; Vernon M Chinchilli; Eugene R Bleecker
Journal:  N Engl J Med       Date:  2010-09-19       Impact factor: 91.245

Review 2.  Guideline-oriented perioperative management of patients with bronchial asthma and chronic obstructive pulmonary disease.

Authors:  Michiaki Yamakage; Sohshi Iwasaki; Akiyoshi Namiki
Journal:  J Anesth       Date:  2008-11-15       Impact factor: 2.078

3.  Structure-guided residence time optimization of a dabigatran reversal agent.

Authors:  Felix Schiele; Joanne van Ryn; Tobias Litzenburger; Michael Ritter; Daniel Seeliger; Herbert Nar
Journal:  MAbs       Date:  2015       Impact factor: 5.857

4.  Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease.

Authors:  Martha C Durham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-07

Review 5.  Acute exacerbations in chronic obstructive pulmonary disease: current strategies with pharmacological therapy.

Authors:  Charles S Hall; Andreas Kyprianou; Alan M Fein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Optimizing bronchodilator therapy in emphysema.

Authors:  Philip T Diaz; Aaron S Bruns; Michael E Ezzie; Nathaniel Marchetti; Byron M Thomashow
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 7.  The pharmacological approach to the elderly COPD patient.

Authors:  Timothy E Albertson; Michael Schivo; Amir A Zeki; Samuel Louie; Mark E Sutter; Mark Avdalovic; Andrew L Chan
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

Review 8.  Treatment of chronic obstructive pulmonary disease in older patients: a practical guide.

Authors:  Abebaw M Yohannes; Christopher C Hardy
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 9.  Safety, tolerability and risk benefit analysis of tiotropium in COPD.

Authors:  Yuji Oba; Tareq Zaza; Danish M Thameem
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 10.  Optimising treatment for COPD--new strategies for combination therapy.

Authors:  T Welte
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.